NYMX - Nymox to file for Fexapotide approval by mid-September

Microcap biotech Nymox Pharmaceutical ([[NYMX]] -2.1%) expects to file for marketing approval for Fexapotide Triflutate in benign prostatic hyperplasia (enlarged prostate) on or before September 15, 2021."The company will file on or before September 15. We hope but cannot be certain that the date may be before September,” CEO Paul Averback said adding, “company management will communicate updates where appropriate."In June 2020, Nymox anticipated the submission of the marketing application by late Q3 or early Q4 2020 despite COVID-related disruptions.Announcing the guidance on marketing application, the CEO previously said, "The last major drug innovations for BPH (alpha-blockers and 5-ARIs) were first introduced over 30 years ago. If our work was an easy task, others would have accomplished this decades ago."

For further details see:

Nymox to file for Fexapotide approval by mid-September